A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions
- DRUG: Giredestrant
- DRUG: Fulvestrant or an Aromatase Inhibitor (Physician Choice)
- DRUG: LHRH Agonist
Sponsor
Hoffmann-La Roche